Use of PCa genetic testing to stratify risk and guide screening and management continues to gain momentum.
The new report adds to growing evidence of COVID-19’s adverse effects on the kidneys.
An assay that measures tumor-derived cell-free DNA in plasma discriminated between patients with and without renal cell carcinoma with 99% accuracy.
In men with nonmetastatic castration-resistant prostate cancer, a PSA doubling time of less than 3 months vs 15 months or more increases the risk of metastasis, which in turn is associated with a large increase in healthcare utilization and costs.
Multiparametric magnetic resonance imaging is highly accurate in differentiating nonmuscle-invasive from muscle-invasive bladder cancer, according to a new systematic review and meta-analysis.
Patients with prostate cancer who live in rural areas are less likely than their urban counterparts to receive treatment and make follow-up visits after RP.
Patients who experienced acute kidney injury during hospitalization for COVID-19, compared with those who did not, had greater proteinuria and ɑ1-microglobulin excretion at admission, a study found.
Men in the highest tertile of high-sensitivity C-reactive protein level had a 30% increased risk for prostate cancer compared with those in the lowest tertile in adjusted analyses.
A large study of patients hospitalized with COVID-19 found that treatment with hydroxychloroquine alone or with azithromycin decreased the risk of in-hospital death by 66% and 71%, respectively, compared with not receiving either treatment.
SARS-CoV-2, the virus that causes COVID-19, enters cells by binding to ACE2 on cell surfaces. Investigators performed a comparative analysis of specimens of diabetic kidney disease tissue and healthy tissue for ACE2 expression.
